Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211
Разработка средств ядерной медицины, селективных к LAT1, с использованием астата-211
2024-11-18
SCID: 54.1/ec3ngkvq
Discuss with AI
3-[211At]astato-α-methyl-L-tyrosineLAT1-targeted therapeuticsalpha-emitting radionuclideastatine-211nuclear medicine therapy
Figures from the paper
Abstract (AI)
We investigated nuclear medicine therapeutics targeting the L-type amino acid transporter 1 (LAT1). We previously reported that a nuclear medicine therapeutic drug using astatine 211 (211At), an alpha-emitting nuclide that can be produced in an accelerator and targets LAT1 as a molecular target, is effective. The seed compound was 3-[211At] Astato-α-methyl-L-tyrosine (211At-AAMT-OH-L). We used a unique labeling method. By changing the OH group of phenol to a methyl group, retention was successfully increased. It was also found that the amount of the L-isomer taken up by the D-isomer and L-isomer was clearly higher, and the L-isomer was superior as a therapeutic drug. Compounds in which the methyl group was replaced with an ethyl or propyl group were also examined, but their retention did not increase significantly. In fact, we observed increased non-specific accumulation and dynamics, suggesting that labeling may be off. In addition, 211At-AAMT-O-Me-L, which has a simple structure, was clearly superior in terms of uptake speed for several candidate compounds. As a result, we were able to develop a compound that can be easily labeled, has high specific radioactivity, is stable, and has a strong therapeutic effect.
Key Findings
1
Astatine-211-labeled LAT1-targeting compounds were investigated as alpha-emitting nuclear medicine therapeutics.
2
Methylating the phenolic OH group increased compound retention compared with the seed compound 211At-AAMT-OH-L.
3
Replacing the methyl group with ethyl or propyl did not significantly improve retention and increased nonspecific accumulation, suggesting possible labeling problems.
4
The L-isomer showed clearly higher uptake than the D-isomer and was superior for therapeutic development.
5
The simple 211At-AAMT-O-Me-L structure showed superior uptake speed and enabled development of a readily labeled, highly specific, stable compound with strong therapeutic effects.
Research Object
LAT1-targeting astatine-211 nuclear medicine therapeutic compounds, particularly 211At-AAMT-O-Me-L
Research Subject
The effects of structural modifications and stereochemistry on LAT1 uptake, retention, specificity, labeling properties, stability, and therapeutic performance
Publication Details
Publication Date
2024-11-18
Journal
Publisher
ISSN
Cited by
7
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai4
The L-Type Amino Acid Transporter LAT1—An Emerging Target in Cancer2019
Review of the Correlation of LAT1 With Diseases: Mechanism and Treatment2020
Establishment of Stable Cell Lines With High Expression of Heterodimers of Human 4F2hc and Human Amino Acid Transporter LAT1 or LAT2 and Delineation of Their Differential Interaction With ^|^alpha;-Alkyl Moieties2012
Amino Acid-Based Boron Carriers in Boron Neutron Capture Therapy (BNCT)2023